RESTON, Va., Oct. 1, 2018 /PRNewswire-PRWeb/ -- Most clinicians are unclear on the efficacy, substitution, and extrapolation
In total, 3347 specialists and primary care clinicians participated in CCO's online educational program, including oncologists, rheumatologists, gastroenterologists, and dermatologists. CCO identified persistent misunderstandings about biosimilars at baseline.
"These uncovered gaps may explain why some clinicians are unwilling to consider biosimilars as a treatment option for their patients," said Tina B. Stacy, PharmD, BCOP, CHCP, Executive Vice President, Educational Strategy at CCO. "Through this analysis, we have shown that continuing medical education is a viable platform by which to improve clinicians' competence with biosimilars, potentially removing barriers for consideration of their use."
The educational program successfully increased clinicians' understanding of and willingness to prescribe biosimilars, potentially removing barriers to the use of these new and potentially less expensive treatment options for patients. The abstracts can be viewed at https://bit.ly/2xLerzH and https://bit.ly/2xoGlBw
About Clinical Care Options Clinical Care Options, LLC, is a global leader in the development of innovative educational programs and technology platforms. CCO's team has been a pioneer in the creation of continuing education and decision support resources for healthcare professionals both in the United States and around the world for more than 2 decades. For more information, visit clinicaloptions.com.
Contact: Tradd Sanderson | Director of Marketing Clinical Care Options
SOURCE Clinical Care Options
Subscribe to our Free Newsletters!